Document Detail


Biopsy location for direct immunofluorescence in patients with suspected bullous pemphigoid impacts probability of a positive test result.
MedLine Citation:
PMID:  25348760     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Bullous pemphigoid (BP) is an autoimmune polymorphic skin disease characterized by erythematous papules and plaques and tense bullae. A skin biopsy for direct immunofluorescence (DIF) is used to detect autoantibodies and complement proteins.
OBJECTIVE: We sought to determine which location would provide the highest probability of obtaining a positive DIF result.
METHOD: We undertook a retrospective chart review of 1,423 DIF biopsies. Biopsies with a clinical suspicion of BP were designated as either lesional, perilesional, or indeterminate.
RESULTS: Fifty percent of lesional DIF biopsies were positive, whereas 22% of perilesional and 12% of indeterminate biopsies had a positive DIF result. The odds ratio of a positive DIF from a lesional versus perilesional biopsy site was found to be 3.45 (95% CI 1.44-8.29).
CONCLUSION: Clinicians are more likely to obtain a positive DIF result from a lesional nonbullous skin biopsy than from a perilesional or normal skin biopsy.
Authors:
Chris Sladden; Mark G Kirchhof; Richard I Crawford
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cutaneous medicine and surgery     Volume:  18     ISSN:  1203-4754     ISO Abbreviation:  J Cutan Med Surg     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-10-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9614685     Medline TA:  J Cutan Med Surg     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  392-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quality appraisal of acne clinical practice guidelines, 2008-2013.
Next Document:  Mucocutaneous manifestations of inflammatory bowel disease in Turkey.